Item 5. Other Information
Item 5. Other Information
(a)
Increase in Board Size, Appointment of New Directors and Reconstitution of Board Committees
The Board of Directors (the " Board ") of the Company approved an increase in the size of the Board from six to nine members, creating three vacancies, effective June 15, 2026. The Board filled each of the three newly created vacancies by appointing April Burke, Ana Lucia Bastiani-Posner, and Andrew Costa as directors of the Company, effective June 15, 2026. Before such appointment, the Company engaged Ms. Burke, Ms. Bastiani-Posner, and Mr. Costa to sit on its Advisory Board. Each of Ms. Burke, Ms. Bastiani-Posner, and Mr. Costa will serve until the Company's next annual meeting of shareholders and until their respective successors are duly elected and qualified, or until their earlier resignation or removal.
The Board has determined that each of Ms. Burke, Ms. Bastiani-Posner, and Mr. Costa qualifies as an independent director under Section 803 of the NYSE American Company Guide.
There is no arrangement or understanding between any of Ms. Burke, Ms. Bastiani-Posner, or Mr. Costa and any other person pursuant to which any of them was selected to their respective position. There are no transactions involving the Company and any of Ms. Burke, Ms. Bastiani-Posner, or Mr. Costa that are required to be reported pursuant to Item 404(a) of Regulation S-K. None of Ms. Burke, Ms. Bastiani-Posner, or Mr. Costa has any family relationship with any of the Company's board of directors or executive officers. None of Ms. Burke, Ms. Bastiani-Posner, or Mr. Costa has been involved in any legal proceedings required to be disclosed as enumerated in Item 401(f) of Regulation S-K that occurred during the past ten years.
Biographies
April Burke (Age 52)
April Burke currently serves on the Company's General Advisory Board. Ms. Burke has over 20 years of executive financial leadership experience across consumer-packaged goods, manufacturing and medical device industries. She has served as Chief Financial Officer and senior finance leadership for both public and private companies, where she was responsible for financial strategy, governance and compliance, and operational transformation. She has extensive experience in M&A transactions, including buy-side and sell-side processes, post-acquisition integration, and financial structuring.
36
Ms. Burke is currently the Executive Vice President and CFO at Lucid Hearing, a medical device manufacturer, where she leads all aspects of corporate development, finance, accounting, and treasury. During her tenure, she has led strategic planning initiatives, optimized working capital, strengthened internal controls, and supported enterprise growth through disciplined capital deployment and operational execution.
Earlier in her career, Ms. Burke held senior finance roles at Nutrabolt, Dean Foods, and Cadbury Schweppes, where she gained experience in large-scale manufacturing operations, and complex, multi-channel distribution environments, including pricing and marketing investments.
Ms. Burke also brings significant expertise in financial governance, ERP and finance transformation, and enterprise risk management. She has deep experience presenting to boards of directors, lenders, and institutional stakeholders and has led finance organizations through periods of growth, operational transformation, and regulatory scrutiny.
Ms. Burke holds a BBA in Finance from the McCombs School of Business at The University of Texas at Austin. The company believes Ms. Burke's financial leadership experience, strategic perspective, and operational discipline qualify her to serve on our Board of Directors.
Ana Lucia Bastiani-Posner (Age 54)
Ana Bastiani-Posner currently serves on the Company's General Advisory Board. Ms. Bastiani-Posner is a C-suite executive qualified to serve as a financial expert with over 30 years of experience in Fortune 500 companies and non-profit academic research organization. Ana brings a strong understanding of M&A transactions as she managed efforts for successful completion of large deals in the highly complex and regulated pharmaceutical business. Her experience in M&A includes the proposed mega-merger of Pfizer-Allergan and her leadership spans from deal model generation to synergy identification and business integration. Ms. Bastiani-Posner is also a trusted partner in driving organic growth with experience in business consolidation, scale-up of operations and growth acceleration. She is a highly respected member of the executive team and a strategic partner to the President.
Ms. Bastiani-Posner is the Executive Vice-President and CFO at Kyowa Kirin, Inc., a Japanese pharmaceutical company with North America revenues of approximately $1.2B. As an executive committee member and company officer, Ana leads the strategic direction and implementation of long-term goals. She sponsored business integration, which led to consolidation of legal entities, unified processes, simplification, and growth acceleration. Her leadership enabled the company to triple the business in 5 years. Prior to Kyowa Kirin, Ms. Bastiani-Posner held the position of Senior Vice President, Finance and Administration at the New York Genome Center and served as a member of the executive team. In this role, she oversaw finance, IT, HR, facilities and grants management. She restructured the finance function with clear definition of roles & responsibilities and instilled a strong sense of direction, rigor and process in the management of grants with increase in application and awards by $7M in one year. In the last 20 years, Ms. Bastiani-Posner held positions of increasing responsibility in the pharmaceutical industry at Schering-Plough, Novartis and Allergan across multiple functions including R&D, G&A, commercial finance, and corporate financial planning & analysis. Her diversified experience in finance enabled her to develop a deep knowledge of the pharmaceutical industry and shaped her approach to problem-solving. She demonstrated to be a successful leader with a track record of performance and a results-oriented mindset.
Ms. Bastiani-Posner is originally from Brazil where she began her finance career in the banking industry. She holds a bachelor's degree from the Pontifícia Universidade Católica-RS and a master of international management from Thunderbird School of Global Management. Passionate about ESG Climate, she has demonstrated her commitment to outstanding modern leadership and ESG excellence by completing the Diligent Climate Leadership Certification, presented by the Diligent Institute in 2023. The certification focus on climate risk and related business strategy, the board's related fiduciary obligations, climate-related government regulations, reporting and disclosure requirements, and investor engagement. Ms. Bastiani-Posner is BoardReady certified by Latino Corporate Directors Association. She speaks Portuguese, English, and basic Spanish.
Ms. Bastiani-Posner was previously awarded 2023 NJBIZ Best 50 Women in Business, 2023 Top People Leaders and CHROs by Mogul, and 2022 Top 25 Healthcare Technology Leader of New Jersey by The Healthcare Technology Report. She has also engaged as a member of The Wall Street Journal CFO Network.
37
Andrew Costa (Age 37)
Andrew Costa currently serves on the Company's General Advisory Board. Mr. Costa is a Co-Managing Partner at RX3 Growth Partners (" RX3 "), responsible for overseeing all aspects of the fund's investment process, including sourcing, diligence, investment committee and portfolio management. Prior to RX3, Andrew was the Chief Investment Officer at Roth Capital where he oversaw Roth's holding company investment activity. Prior to joining Roth Capital, Andrew was a Vice President in the Investment Banking Division at Morgan Stanley where he led numerous landmark M&A and equity transactions in the retail, marketplace and eCommerce sectors. Prior to Morgan Stanley, Andrew was an Investment Banker at J.P. Morgan Chase & Co., and prior to that, served as a Captain in the U.S. Air Force. Andrew is a Board member of Therabody, Inc. Mr. Costa graduated from the U.S. Air Force Academy with a B.Sc. in Systems Engineering Management and earned an MBA from USC's Marshall School of Business.
Reconstitution of Board Committees
In connection with the appointment of Ms. Burke, Ms. Bastiani-Posner, and Mr. Costa, the Board reconstituted its committees effective June 15, 2026. The new composition of each committee is as follows:
Audit Committee
Andrew Costa will serve as Chair of the Audit Committee. The remaining members of the Audit Committee are Aaron Farberg, April Burke, and Ana Lucia Bastiani-Posner.
Compensation Committee
Ana Lucia Bastiani-Posner will serve as Chair of the Compensation Committee. The remaining members of the Compensation Committee are Paul Lorenc, Sebastian Purcell, and April Burke.
Nominating and Corporate Governance Committee
Aaron Farberg will serve as Chair of the Nominating and Corporate Governance Committee. The remaining members of the Nominating and Corporate Governance Committee are Sebastian Purcell, Paul Lorenc, and Andrew Costa.
Board Member Agreements with the New Directors
In connection with their appointments, each of Ms. Burke, Ms. Bastiani-Posner, and Mr. Costa (each, a " New Director ") has entered into a board member agreement (each, a " Board Member Agreement ") with the Company, the material terms of which are summarized as follows:
Base Retainer. Each New Director is entitled to a quarterly cash retainer of $12,500, representing a total annual retainer of $50,000.
Committee Fees. In addition to the base retainer, each New Director is entitled to receive additional annual cash compensation for service on Board committees. For membership on a committee, the annual fees are as follows: Audit Committee - $7,500; Compensation Committee - $6,000; and Nominating and Corporate Governance Committee - $5,000. If a New Director serves as the chair of a committee, the following annual fees are payable in lieu of the applicable member fee: Audit Committee Chair - $15,000; Compensation Committee Chair - $12,000; and Nominating and Corporate Governance Committee Chair - $7,500. All committee fees are paid quarterly in arrears, together with the quarterly Board retainer.
As such, April Burke will receive an annual Audit Committee membership fee of $7,500 and an annual Compensation Committee membership fee of $6,000, for total annual committee fees of $13,500. Ana Lucia Bastiani-Posner will receive an annual Compensation Committee Chair fee of $12,000 and an annual Audit Committee membership fee of $7,500, for total annual committee fees of $19,500. Andrew Costa will receive an annual Audit Committee Chair fee of $15,000 and an annual Nominating and Corporate Governance Committee membership fee of $5,000, for total annual committee fees of $20,000.
RSU Grant . Each New Director is entitled to receive an annual equity grant of restricted stock units (" RSUs ") under the Company's Stock Incentive Plan (the " Plan "), with a grant date value of $100,000, awarded at the conclusion of each 12-month period from the date of the applicable Board Member Agreement. The RSUs vest at a rate of 25% per quarter over the 12-month period following the applicable grant date, subject to the New Director's Continuous Service (as defined in the Board Member Agreement) on each vesting date. The number of RSUs to be granted is calculated by dividing the applicable grant date value by the Fair Market Value (as defined in the Plan) of the Company's common stock on the date of grant, rounded down to the nearest whole share.
38
Change of Control . All then-outstanding and unvested RSUs held by a New Director will vest in full immediately prior to the closing of a Change in Control (as defined in the Plan), provided such director remains in Continuous Service through such date.
Discretionary Acceleration. The Compensation Committee retains sole discretion to recommend to the Board acceleration of the vesting of any or all outstanding RSU awards held by a New Director in circumstances it determines to be appropriate, including a Board restructuring initiated by the Company, a New Director's resignation required due to a conflict-of-interest recusal at the Company's request, or such other circumstances as the Compensation Committee deems equitable.
Death or Disability. In the event of a New Director's death or permanent disability during the term of their Board Member Agreement, all then-outstanding and unvested RSUs will vest on a pro-rata basis, calculated as the number of months of Continuous Service completed in the applicable vesting period divided by the total months in the vesting period, multiplied by the total unvested RSUs in that period, with settlement occurring within 30 days of the qualifying event. For these purposes, "permanent disability" means the New Director's inability to perform their duties as a board member for a period of 180 consecutive days due to physical or mental incapacity, as determined by a licensed physician.
Forfeiture. Upon termination of Continuous Service for any reason other than death, disability, or a Change in Control, any RSUs that have not vested as of the effective date of such termination will be immediately and automatically forfeited without consideration and returned to the Plan, and no pro-rata vesting will apply to annual RSU grants upon voluntary resignation.
Director Stock Ownership Guidelines. Each New Director is expected to achieve and maintain a minimum level of equity ownership in the Company equal to five times (5x) the annual cash retainer (the " Ownership Guideline ") within five years of the later of the effective date of their Board Member Agreement or the date of any future increase to the Ownership Guideline. Based on the current annual retainer of $50,000, this equates to an Ownership Guideline of $250,000 in Company equity value. Until the Ownership Guideline is met, each New Director is expected to retain at least 50% of net shares received upon the vesting or exercise of any Company equity award, after withholding for applicable taxes.
Reimbursement. The Company will reimburse each New Director for reasonable and documented out-of-pocket expenses incurred in connection with Board service, subject to prior written approval for any single expense exceeding $500, with reimbursement requests submitted within 30 days of the expense being incurred and accompanied by supporting receipts.
The foregoing descriptions of the Board Member Agreements are qualified in their entirety by reference to the full text of such agreements, copies of which are attached hereto as Exhibits 10.1, 10.2, and 10.3, respectively, and incorporated herein by reference.
Updated Compensation Arrangements for Existing Non-Employee Directors
Effective June 15, 2026, the Board approved updated compensation arrangements for each of Jeff Sharpe, Sebastian Purcell, Ph.D., Dr. Z. Paul Lorenc and Dr. Aaron Farberg (collectively, the “ Existing Non-Employee Directors ”) and sent each of them a board compensation notice (each, a “ Board Compensation Notice ”) on June 15, 2026, the material terms of which are summarized as follows:
Jeff Sharpe
Mr. Sharpe is entitled to receive an annual base board retainer of $50,000 and an annual Board Chair premium of $50,000, each payable quarterly in arrears, for aggregate annual cash compensation of $100,000. Committee-specific member fees do not apply to the Board Chairman.
39
Mr. Sharpe is entitled to receive an annual equity grant of RSUs under the Company’s Plan, with a grant date value of $150,000, awarded at the conclusion of each 12-month period from the effective date of his Board Compensation Notice. RSUs vest at a rate of 25% per quarter over the 12-month period following the grant date, subject to Mr. Sharpe’s Continuous Service (as defined in the Board Compensation Notice) on each applicable vesting date. The number of RSUs granted is calculated by dividing the grant date value by the Fair Market Value (as defined in the Plan) of the Company’s common stock on the date of grant, rounded down to the nearest whole share. Mr. Sharpe’s total annual compensation (cash and equity combined) is $250,000.
Sebastian Purcell, Ph.D., Dr. Z. Paul Lorenc and Dr. Aaron Farberg
Each of Sebastian Purcell, Ph.D., Dr. Z. Paul Lorenc and Dr. Aaron Farberg is entitled to receive an annual base board retainer of $50,000, payable quarterly in arrears. Each of Mr. Purcell and Dr. Lorenc serves as a member of both the Compensation Committee and the Nominating and Corporate Governance Committee, for which they each receive additional annual committee membership fees of $6,000 and $5,000, respectively, also payable quarterly in arrears, for aggregate annual committee fees of $11,000 per director. Dr. Farberg serves as a member of the Audit Committee and Chair of the Nominating and Corporate Governance Committee, for which he receives additional annual committee membership fees of $7,500 and $7,500, respectively, also payable quarterly in arrears, for aggregate annual committee fees of $15,000.
Each of Mr. Purcell, Dr. Lorenc and Aaron Farberg is entitled to receive an annual equity grant of RSUs under the Plan, with a grant date value of $100,000, awarded at the conclusion of each 12-month period from the effective date of their respective Board Compensation Notice. RSUs vest at a rate of 25% per quarter over the 12-month period following the grant date, subject to Continuous Service on each applicable vesting date. The number of RSUs is calculated by dividing the grant date value by the Fair Market Value (as defined in the Plan) of the Company’s common stock on the date of grant, rounded down to the nearest whole share. The total annual compensation (cash and equity combined) for each of Mr. Purcell and Dr. Lorenc is $161,000, and for Dr. Farberg is $165,000.
Provisions Applicable to All Existing Non-Employee Directors
Change of Control . All then-outstanding and unvested RSUs held by an Existing Non-Employee Directors will vest in full immediately prior to the closing of a Change in Control (as defined in the Plan), provided such director remains in Continuous Service through such date.
Discretionary Acceleration. The Compensation Committee retains sole discretion to recommend to the Board acceleration of the vesting of any or all outstanding RSU awards held by an Existing Non-Employee Directors in circumstances it determines to be appropriate, including a Board restructuring initiated by the Company, an Existing Non-Employee Director's resignation required due to a conflict-of-interest recusal at the Company's request, or such other circumstances as the Compensation Committee deems equitable.
Death or Disability. In the event of an Existing Non-Employee Director's death or permanent disability during the term of their service, all then-outstanding and unvested RSUs will vest on a pro-rata basis, calculated as the number of months of Continuous Service completed in the applicable vesting period divided by the total months in the vesting period, multiplied by the total unvested RSUs in that period, with settlement occurring within 30 days of the qualifying event. For these purposes, "permanent disability" means the Existing Non-Employee Director's inability to perform their duties as a board member for a period of 180 consecutive days due to physical or mental incapacity, as determined by a licensed physician.
Forfeiture. Upon termination of Continuous Service for any reason other than death, disability, or a Change in Control, any RSUs that have not vested as of the effective date of such termination will be immediately and automatically forfeited without consideration and returned to the Plan, and no pro-rata vesting will apply to annual RSU grants upon voluntary resignation.
Director Stock Ownership Guidelines. The Ownership Guideline for each Existing Non-Employee Director is equal to five times (5x) their respective total annual cash retainer. For each of Mr. Purcell, Dr. Lorenc and Dr. Farberg, whose annual cash retainer is $50,000, the applicable Ownership Guideline is $250,000 in Company equity value. For Mr. Sharpe, whose annual cash retainer is $100,000 (comprising the $50,000 base board retainer and the $50,000 Board Chair Premium), the applicable Ownership Guideline is $500,000 in Company equity value. Each Existing Non-Employee Director is expected to achieve and maintain their respective Ownership Guideline within five years of the later of the effective date of their Board Compensation Notice or the date of any future increase to the Ownership Guideline. Until the Ownership Guideline is met, each Existing Non-Employee Director is expected to retain at least 50% of net shares received upon the vesting or exercise of any Company equity award, after withholding applicable taxes.
40
The foregoing descriptions of the Board Compensation Notices are qualified in their entirety by reference to the full text of such notices, copies of which are attached hereto as Exhibits 10.4, 10.5, 10.6 and 10.7, respectively, and incorporated herein by reference.
Appointment of Chief Commercial Officer
The Board appointed David Bogart as the Chief Commercial Officer (" CCO ") of the Company, effective June 15, 2026. Mr. Bogart will continue to serve as a member of the Board in his existing capacity as a director of the Company.
Mr. Bogart (Age 56) was appointed as a director of the Company on November 13, 2023. He founded Conexeu to commercialize the CXU™ ECM scaffold IP into a market-ready platform. Under his leadership, the Company secured its core patent portfolio locking in worldwide rights to the patented technology that positions and assembled a world-class team, positioning Conexeu at the forefront of the regenerative aesthetics and tissue engineering market. David Bogart brings extensive expertise in capital markets, corporate finance, and strategic business development to his role as a director of Conexeu. He has facilitated numerous private and public market transactions, including IPOs, reverse mergers, and M&A deals, collectively raising over $100 million. Mr. Bogart's background in investor relations and public market strategy enables him to formulate impactful commercial roadmaps and distribution networks for emerging biotech products. He specializes in refining go-to-market plans that balance accelerated revenue growth with regulatory compliance. Throughout his career, Mr. Bogart has guided teams in building strong partnerships, nurturing investor confidence, and expanding global market footprints.
There is no arrangement or understanding between Ms. Bogart and any other person pursuant to which he was selected to this position. Except as otherwise disclosed under this Quarterly Report and as disclosed under the Company's Registration Statement on Form S-1, as amended, originally filed with the SEC on November 28, 2025, there are no other transactions involving the Company and Mr. Bogart that are required to be reported pursuant to Item 404(a) of Regulation S-K. Mr. Bogart does not have any family relationship with any of the Company's board of directors or executive officers. Mr. Bogart has not been involved in any legal proceedings required to be disclosed as enumerated in Item 401(f) of Regulation S-K that occurred during the past ten years.
Executive Employment Agreement
In connection with his appointment as CCO, Mr. Bogart entered into an executive employment agreement (the " Executive Employment Agreement ") with the Company, effective as of June 15, 2026. Under the Executive Employment Agreement, Mr. Bogart is responsible for performing all duties consistent with the position of CCO and such other reasonable duties as may be assigned to him by the CEO or the Board.
Mr. Bogart is entitled to an annual base salary of not less than US$270,000 as the Initial Base Salary. The Board may consider increases to the base salary upon the achievement of defined commercial and business milestones. Mr. Bogart is also eligible to earn milestone-based bonuses as a percentage of his base salary then in effect at the sole discretion of the Board. An initial cash bonus milestone of US$37,500 is payable upon the completion of a financing of at least US$20 million at a minimum pre-money market capitalization of US$150 million (or, if the financing completed is a minimum of US$15 million at such minimum pre-money market capitalization, two-thirds of such amount, being US$24,750), as further described in the Executive Employment Agreement.
In addition, Mr. Bogart will maintain the milestone-based performance warrants previously issued to him and will be awarded an additional equity award of up to a maximum of 0.75% of the Company's common shares on an issued and outstanding basis at the time of the equity grant. This milestone-based equity award of up to 0.75% of the Company's issued and outstanding equity securities is earned upon receipt of FDA clearance or approval (including 510(k) clearance or PMA approval) for a product utilizing the Company's extracellular matrix technology with human collagen, intended for an aesthetic application or indication. The milestone-based equity award vests immediately upon achieving the applicable milestone, subject to the Company first receiving shareholder approval and any required regulatory authority approval, and is subject to automatic full vesting acceleration upon a non-public change of control, subject to the same shareholder and regulatory approvals.
The Executive Employment Agreement provides for at-will employment. Accordingly, either party may terminate the agreement at any time, with or without cause, upon written notice of termination. Upon termination for any reason, Mr. Bogart is required to resign from all positions and terminate any relationships as an employee, advisor, officer, or director with the Company. Upon termination, we will pay all Accrued Obligations (as defined in the Executive Employment Agreement). If we terminate Mr. Bogart's employment without cause, or if he resigns for good reason, and provided he remains in compliance with the agreement, he will be entitled to Severance Benefits (as defined in the Executive Employment Agreement), in addition to the Accrued Obligations, consisting of cash severance equal to 12 months of the Initial Base Salary. Such Severance Benefits will be paid in accordance with the Company's regularly scheduled payroll over the 12-month period following his separation from service, subject to the effectiveness of a separation agreement. If Mr. Bogart resigns without good reason, if we terminate his employment for cause, or upon his death or disability, then (i) all compensation payments will cease immediately (other than amounts already earned), and (ii) he will not be entitled to any Severance beyond the Accrued Obligations.
41
Mr. Bogart has entered into a non-disclosure, non-solicit, and non-compete agreement with Conexeu which provides for certain non-disclosure, non-solicit, and non-compete covenants that will survive termination of the Executive Employment Agreement for a period of 12 months, with the restricted territory being North America.
The foregoing description of the Executive Employment Agreement is qualified in their entirety by reference to the full text of such agreements, copy of which is attached hereto as Exhibit 10.8, and incorporated herein by reference.
(b) Not applicable.
(c)
During our fiscal quarter ended April 30, 2026, none of our directors or executive officers
adopted
, modified or
terminated
any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any "non-Rule 10b5-1 trading arrangement" as defined in Item 408(c) of Regulation S-K.
Item 6. Exhibits
The following exhibits are included with this Quarterly Report:
Exhibit No.
Description of Exhibit
10.1 * +‡
Board Member Agreement between Conexeu Sciences Inc. and April Burke, dated June 15, 2026
10.2 * +‡
Board Member Agreement between Conexeu Sciences Inc. and Ana Lucia Bastiani-Posner, dated June 15, 2026
10.3 * +‡
Board Member Agreement between Conexeu Sciences Inc. and Andrew Costa, dated June 15, 2026
10.4 * +
Board Compensation Notice to Dr. Z. Paul Lorenc, dated June 15, 2026
10.5 * +
Board Compensation Notice to Jeff Sharpe, dated June 15, 2026
10.6 * +
Board Compensation Notice to Sebastian Purcell, dated June 15, 2026
10.7 * +
Board Compensation Notice to Dr. Aaron Farberg, dated June 15, 2026
10.8 * +
Executive Employment Agreement between Conexeu Sciences Inc. and David Bogart, dated June 15, 2026
31.1 *
Certification of Chief Executive Officer pursuant to the Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14(a).
31.2 *
Certification of Chief Financial Officer pursuant to the Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14(a).
32.1 **
Certifications pursuant to the Securities Exchange Act of 1934 Rule 13a-14(b) or 15d-14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS *
Inline XBRL Instance Document-the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document
101.SCH *
Inline XBRL Taxonomy Extension Schema Document
101.CAL *
Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF *
Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB *
Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE *
Inline XBRL Taxonomy Extension Presentation Linkbase Document
104 *
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101 attachments)
Notes:
* Filed herewith.
** Furnished herewith
+ Indicates a management contract or compensatory plan
‡ Portions of this exhibit have been omitted.
42
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
CONEXEU SCIENCES INC.
Date: June 15, 2026
By:
/s/ Miles Harrison
Name:
Miles Harrison
Title:
Chief Executive Officer
(Principal Executive Officer) and
Director
Date: June 15, 2026
By:
/s/ Stephen D. Inouye
Name:
Stephen D. Inouye
Title:
Chief Financial Officer
(Principal Financial Officer and
Principal Accounting Officer) and
Secretary and Treasurer
4 3